Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 13, 2009 - Issue 7
Submit an article Journal homepage
360
Views
35
CrossRef citations to date
0
Altmetric
Reviews

Targeting histone deacetylases for heart failure

Erik W Bush Gilead Colorado, Inc., 3333 Walnut Street, Boulder, Colorado 80301, USA +1 303 533 1736; +1 303 410 6669; [email protected]; [email protected]
&
Timothy A McKinsey Gilead Colorado, Inc., 3333 Walnut Street, Boulder, Colorado 80301, USA +1 303 533 1736; +1 303 410 6669; [email protected]; [email protected]
Pages 767-784 | Published online: 26 May 2009

Bibliography

  • Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23
  • Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996;272:408-11
  • Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003;19:286-93
  • Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002;277:25748-55
  • Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31
  • Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8
  • Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006;126:257-68
  • Wettschureck N, Rutten H, Zywietz A, et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nat Med 2001;7:1236-40
  • Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6
  • Gardin JM, Lauer MS. Left ventricular hypertrophy: the next treatable, silent killer? JAMA 2004;292:2396-8
  • Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004;109:1580-9
  • McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 2002;27:40-7
  • Kolodziejczyk SM, Wang L, Balazsi K, et al. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol 1999;9:1203-6
  • Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA 2000;97:4070-5
  • Passier R, Zeng H, Frey N, et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000;105:1395-406
  • Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002;110:479-88
  • Xu J, Gong NL, Bodi I, et al. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J Biol Chem 2006;281:9152-62
  • Han A, Pan F, Stroud JC, et al. Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2. Nature 2003;422:730-4
  • Han A, He J, Wu Y, et al. Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J Mol Biol 2005;345:91-102
  • Backs J, Song K, Bezprozvannaya S, et al. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 2006;116:1853-64
  • Bush E, Fielitz J, Melvin L, et al. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc Natl Acad Sci USA 2004;101:2870-5
  • Vega RB, Harrison BC, Meadows E, et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 2004;24:8374-85
  • Chang S, McKinsey TA, Zhang CL, et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004;24:8467-76
  • Davis FJ, Gupta M, Camoretti-Mercado B, et al. Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4. Implications in cardiac muscle gene regulation during hypertrophy. J Biol Chem 2003;278:20047-58
  • Xing W, Zhang TC, Cao D, et al. Myocardin induces cardiomyocyte hypertrophy. Circ Res 2006;98:1089-97
  • Dai YS, Xu J, Molkentin JD. The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment. Mol Cell Biol 2005;25:9936-48
  • Song K, Backs J, McAnally J, et al. The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 2006;125:453-66
  • Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 2003;92:1079-88
  • Gupta MP, Samant SA, Smith SH, Shroff SG. HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity. J Biol Chem 2008;283:10135-46
  • Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA 2000;97:7835-40
  • Nishino TG, Miyazaki M, Hoshino H, et al. 14-3-3 regulates the nuclear import of class IIa histone deacetylases. Biochem Biophys Res Commun 2008;377:852-6
  • Johannes FJ, Prestle J, Eis S, et al. PKCu is a novel, atypical member of the protein kinase C family. J Biol Chem 1994;269:6140-8
  • Valverde AM, Sinnett-Smith J, Van LJ, Rozengurt E. Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc Natl Acad Sci USA 1994;91:8572-6
  • Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34
  • Huynh QK, McKinsey TA. Protein kinase D directly phosphorylates histone deacetylase 5 via a random sequential kinetic mechanism. Arch Biochem Biophys 2006;450:141-8
  • Sucharov CC, Dockstader K, McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell 2008;19:4141-53
  • Rozengurt E, Rey O, Waldron RT. Protein kinase D signaling. J Biol Chem 2005;280:13205-8
  • Carnegie GK, Soughayer J, Smith FD, et al. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell 2008;32:169-79
  • Harrison BC, Kim MS, van RE, et al. Regulation of cardiac stress signaling by protein kinase D1. Mol Cell Biol 2006;26:3875-88
  • Iwata M, Maturana A, Hoshijima M, et al. PKCϵ–PKD1 signaling complex at Z-discs plays a pivotal role in the cardiac hypertrophy induced by G-protein coupling receptor agonists. Biochem Biophys Res Commun 2005;327:1105-13
  • Fielitz J, Kim MS, Shelton JM, et al. Requirement of protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci USA 2008;105:3059-63
  • Bossuyt J, Helmstadter K, Wu X, et al. Ca2+/calmodulin-dependent protein kinase IIδ and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 2008;102:695-702
  • Berdeaux R, Goebel N, Banaszynski L, et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med 2007;13:597-603
  • Martini JS, Raake P, Vinge LE, et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA 2008;105:12457-62
  • Chang S, Bezprozvannaya S, Li S, Olson EN. An expression screen reveals modulators of class II histone deacetylase phosphorylation. Proc Natl Acad Sci USA 2005;102:8120-5
  • Dequiedt F, Martin M, Von Blume J, et al. New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone deacetylases. Mol Cell Biol 2006;26:7086-102
  • McKinsey TA. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res 2007;73:667-77
  • Zhang T, Miyamoto S, Brown JH. Cardiomyocyte calcium and calcium/calmodulin-dependent protein kinase II: friends or foes? Recent Prog Horm Res 2004;59:141-68
  • Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005;11:409-17
  • Backs J, Backs T, Neef S, et al. The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 2009;106:2342-7
  • Backs J, Backs T, Bezprozvannaya S, et al. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol Cell Biol 2008;28:3437-45
  • Zhang T, Kohlhaas M, Backs J, et al. CaMKIIδ isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem 2007;282:35078-87
  • Ago T, Liu T, Zhai P, et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008;133:978-93
  • Illi B, Dello RC, Colussi C, et al. Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ Res 2008;102:51-8
  • Martin M, Potente M, Janssens V, et al. Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc Natl Acad Sci USA 2008;105:4727-32
  • Paroni G, Cernotta N, Dello RC, et al. PP2A regulates HDAC4 nuclear import. Mol Biol Cell 2008;19:655-67
  • Sucharov CC, Langer S, Bristow M, Leinwand L. Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A. Am J Physiol Cell Physiol 2006;291:C1029-37
  • Liu F, Dowling M, Yang XJ, Kao GD. Caspase-mediated specific cleavage of human histone deacetylase 4. J Biol Chem 2004;279:34537-46
  • Paroni G, Mizzau M, Henderson C, et al. Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Mol Biol Cell 2004;15:2804-18
  • Paroni G, Fontanini A, Cernotta N, et al. Dephosphorylation and caspase processing generate distinct nuclear pools of histone deacetylase 4. Mol Cell Biol 2007;27:6718-32
  • Scott FL, Fuchs GJ, Boyd SE, et al. Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function. J Biol Chem 2008;283:19499-510
  • Qin L, Zeng H, Zhao D. Requirement of protein kinase D Tyrosine phosphorylation for VEGF-A165-induced angiogenesis through its interaction and regulation of phospholipase Cγ Phosphorylation. J Biol Chem 2006;281:32550-8
  • Wong C, Jin ZG. Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J Biol Chem 2005;280:33262-9
  • Ha CH, Wang W, Jhun BS, et al. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem 2008;283:14590-9
  • Wang S, Li X, Parra M, et al. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci USA 2008;105:7738-43
  • Xu X, Ha CH, Wong C, et al. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler Thromb Vasc Biol 2007;27:2355-62
  • Kim MS, Wang F, Puthanveetil P, et al. Protein kinase D is a key regulator of cardiomyocyte lipoprotein lipase secretion after diabetes. Circ Res 2008;103:252-60
  • Sumara G, Formentini I, Collins S, et al. Regulation of PKD by the MAPK p38δ in insulin secretion and glucose homeostasis. Cell 2009;136:235-48
  • Rotenberg A, Mayford M, Hawkins RD, et al. Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus. Cell 1996;87:1351-61
  • Nghiem P, Ollick T, Gardner P, Schulman H. Interleukin-2 transcriptional block by multifunctional Ca2+/calmodulin kinase. Nature 1994;371:347-50
  • Chin ER. Role of Ca2+/ calmodulin-dependent kinases in skeletal muscle plasticity. J Appl Physiol 2005;99:414-23
  • Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell 2000;6:233-44
  • McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 2001;11:497-504
  • Mejat A, Ramond F, Bassel-Duby R, et al. Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat Neurosci 2005;8:313-21
  • Takahashi-Fujigasaki J, Arai K, Funata N, Fujigasaki H. SUMOylation substrates in neuronal intranuclear inclusion disease. Neuropathol Appl Neurobiol 2006;32:92-100
  • Bolger TA, Yao TP. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci 2005;25:9544-53
  • Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science 2009;323:256-9
  • Majdzadeh N, Wang L, Morrison BE, et al. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 2008;68:1076-92
  • Zhang X, Chen HM, Jaramillo E, et al. Histone deacetylase-related protein inhibits AES-mediated neuronal cell death by direct interaction. J Neurosci Res 2008;86:2423-31
  • Morrison BE, Majdzadeh N, Zhang X, et al. Neuroprotection by histone deacetylase-related protein. Mol Cell Biol 2006;26:3550-64
  • Hoshino M, Tagawa K, Okuda T, et al. Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein. J Neurochem 2003;87:257-67
  • Linseman DA, Bartley CM, Le SS, et al. Inactivation of the myocyte enhancer factor-2 repressor histone deacetylase-5 by endogenous Ca2+/calmodulin-dependent kinase II promotes depolarization-mediated cerebellar granule neuron survival. J Biol Chem 2003;278:41472-81
  • Guan Z, Giustetto M, Lomvardas S, et al. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 2002;111:483-93
  • Vega RB, Matsuda K, Oh J, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004;119:555-66
  • Jeon EJ, Lee KY, Choi NS, et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006;281:16502-11
  • Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006;126:321-34
  • Kato H, Tamamizu-Kato S, Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1α and increases transcriptional activity. J Biol Chem 2004;279:41966-74
  • Dequiedt F, Kasler H, Fischle W, et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003;18:687-98
  • Dequiedt F, Van LJ, Lecomte E, et al. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J Exp Med 2005;201:793-804
  • Parra M, Kasler H, McKinsey TA, et al. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem 2005;280:13762-70
  • Parra M, Mahmoudi T, Verdin E. Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. Genes Dev 2007;21:638-43
  • Antos CL, McKinsey TA, Dreitz M, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003;278:28930-7
  • Zhang CL, McKinsey TA, Lu JR, Olson EN. Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J Biol Chem 2001;276:35-9
  • Sparrow DB, Miska EA, Langley E, et al. MEF-2 function is modified by a novel co-repressor, MITR. EMBO J 1999;18:5085-98
  • Fischle W, Dequiedt F, Fillion M, et al. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 2001;276:35826-35
  • Fischle W, Dequiedt F, Hendzel MJ, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002;9:45-57
  • Jones P, Altamura S, De FR, et al. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett 2008;18:1814-9
  • Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 2007;104:17335-40
  • Schultz BE, Misialek S, Wu J, et al. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry 2004;43:11083-91
  • Lagger G, O'Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-81
  • Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-802
  • Montgomery RL, Potthoff MJ, Haberland M, et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008;118:3588-97
  • Trivedi CM, Luo Y, Yin Z, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity. Nat Med 2007;13:324-31
  • Kee HJ, Eom GH, Joung H, et al. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ Res 2008;103:1259-69
  • Trivedi CM, Lu MM, Wang Q, Epstein JA. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J Biol Chem 2008;283:26484-9
  • Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9:206-18
  • Gupta P, Ho PC, Ha SG, et al. HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3. PLoS ONE 2009;4:e4363. Published online 10 February 2009, doi:10.1371/journal.pone.0004363
  • Kook H, Lepore JJ, Gitler AD, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003;112:863-71
  • Kee HJ, Sohn IS, Nam KI, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006;113:51-9
  • Kong Y, Tannous P, Lu G, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006;113:2579-88
  • Lee TM, Lin MS, Chang NC. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol 2007;293:H968-77
  • Gallo P, Latronico MV, Gallo P, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res 2008;80:416-24
  • van Empel VP, Bertrand AT, Hofstra L, et al. Myocyte apoptosis in heart failure. Cardiovasc Res 2005;67:21-9
  • Granger A, Abdullah I, Huebner F, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008;22:3549-60
  • Zhao TC, Cheng G, Zhang LX, et al. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc Res 2007;76:473-81
  • Daosukho C, Chen Y, Noel T, et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. Free Radic Biol Med 2007;42:1818-25
  • Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62
  • Rombouts K, Niki T, Greenwel P, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-β1-induced fibrogenesis in skin fibroblasts. Exp Cell Res 2002;278:184-97
  • Liu F, Levin MD, Petrenko NB, et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol 2008;45:715-23
  • Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J Am Soc Nephrol 2007;18:58-65
  • Adcock IM, Tsaprouni L, Bhavsar P, Ito K. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007;19:694-700
  • Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 2005;10:197-204
  • Kinugawa K, Minobe WA, Wood WM, et al. Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation 2001;103:1089-94
  • Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000;86:386-90
  • Nakao K, Minobe W, Roden R, et al. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997;100:2362-70
  • Fitzsimons DP, Patel JR, Moss RL. Role of myosin heavy chain composition in kinetics of force development and relaxation in rat myocardium. J Physiol 1998;513(Pt 1):171-83
  • Herron TJ, McDonald KS. Small amounts of α-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res 2002;90:1150-2
  • Korte FS, Herron TJ, Rovetto MJ, McDonald KS. Power output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts. Am J Physiol Heart Circ Physiol 2005;289:H801-12
  • James J, Martin L, Krenz M, et al. Forced expression of α-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions. Circulation 2005;111:2339-46
  • Mansen A, Yu F, Forrest D, et al. TRs have common and isoform-specific functions in regulation of the cardiac myosin heavy chain genes. Mol Endocrinol 2001;15:2106-14
  • Morkin E. Control of cardiac myosin heavy chain gene expression. Microsc Res Tech 2000;50:522-31
  • Davis FJ, Pillai JB, Gupta M, Gupta MP. Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of α-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility. Am J Physiol Heart Circ Physiol 2005;288:H1477-90
  • Danzi S, Dubon P, Klein I. Effect of serum triiodothyronine on regulation of cardiac gene expression: role of histone acetylation. Am J Physiol Heart Circ Physiol 2005;289:H1506-11
  • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
  • Kristeleit R, Fong P, Aherne GW, de Bono J. Histone deacetylase inhibitors: emerging anticancer therapeutic agents? Clin Lung Cancer 2005;7(Suppl 1):S19-30
  • Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004;10:2289-98
  • Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997-4003
  • Byrd JC, Marcucci G, Parthun MR, et al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105:959-67
  • Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-73
  • Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res 2006;12:3871-4
  • Molife R, Fong P, Scurr M, et al. HDAC inhibitors and cardiac safety. Clin Cancer Res 2007;13:1068-9
  • Pasqualucci L, Bereschenko O, Niu H, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma 2003;44(Suppl 3):S5-12
  • Halkidou K, Gaughan L, Cook S, et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-89
  • Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-58
  • Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 2005;94:11-6
  • Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6
  • Douer D. Transcription therapy for acute promyelocytic leukaemia. Expert Opin Investig Drugs 2000;9:329-46
  • Pandolfi PP. Transcription therapy for cancer. Oncogene 2001;20:3116-27
  • Herranz M, Esteller M. New therapeutic targets in cancer: the epigenetic connection. Clin Transl Oncol 2006;8:242-9
  • Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 2005;27:408-15
  • Depre C, Wang Q, Yan L, et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 2006;114:1821-8
  • Waltregny D, Glenisson W, Tran SL, et al. Histone deacetylase HDAC8 associates with smooth muscle α-actin and is essential for smooth muscle cell contractility. FASEB J 2005;19:966-8
  • Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-18
  • Margueron R, Duong V, Castet A, Cavailles V. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 2004;68:1239-46
  • Korkmaz CG, Fronsdal K, Zhang Y, et al. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation–rescue of transcriptionally compromised mutants. J Endocrinol 2004;182:377-89
  • Dinarello CA. Inhibitors of histone deacetylases as anti-inflammatory drugs. Ernst Schering Res Found Workshop 2006;56:45-60
  • Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2:551-8
  • Sadri-Vakili G, Cha JH. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res 2006;3:403-8
  • Hirtz D, Iannaccone S, Heemskerk J, et al. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 2005;65:1352-7
  • Tagawa H, Wang N, Narishige T, et al. Cytoskeletal mechanics in pressure-overload cardiac hypertrophy. Circ Res 1997;80:281-9
  • Sato H, Nagai T, Kuppuswamy D, et al. Microtubule stabilization in pressure overload cardiac hypertrophy. J Cell Biol 1997;139:963-73
  • Hein S, Kostin S, Heling A, et al. The role of the cytoskeleton in heart failure. Cardiovasc Res 2000;45:273-8
  • Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38
  • Field ML, Clark JF. Inappropriate ubiquitin conjugation: a proposed mechanism contributing to heart failure. Cardiovasc Res 1997;33:8-12
  • Zolk O, Schenke C, Sarikas A. The ubiquitin-proteasome system: focus on the heart. Cardiovasc Res 2006;70:410-21
  • Willis MS, Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 2006;41:567-79
  • Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100:4389-94
  • Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999;13:2570-80
  • Kaeberlein M, McVey M, Guarente L: Using yeast to discover the fountain of youth. Sci Aging Knowledge Environ 2001;2001:e1. Published online 3 October 2001, doi: 10.1126/sageke.2001.1.pe1
  • Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004;101:15998-6003
  • Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001;410:227-30
  • Lombard DB, Chua KF, Mostoslavsky R, et al. DNA repair, genome stability, and aging. Cell 2005;120:497-512
  • Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003;100:10794-9
  • McBurney MW, Yang X, Jardine K, et al. The mammalian SIR2α protein has a role in embryogenesis and gametogenesis. Mol Cell Biol 2003;23:38-54
  • Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001;107:137-48
  • Vaziri H, Dessain SK, Ng EE, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59
  • Alcendor RR, Kirshenbaum LA, Imai S, et al. Silent information regulator 2α, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004;95:971-80
  • Alcendor RR, Gao S, Zhai P, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-21
  • Grozinger CM, Chao ED, Blackwell HE, et al. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001;276:38837-43
  • Bitterman KJ, Anderson RM, Cohen HY, et al. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002;277:45099-107
  • Pillai JB, Chen M, Rajamohan SB, et al. Activation of SIRT1, a class III histone deacetylase, contributes to fructose feeding-mediated induction of the α-myosin heavy chain expression. Am J Physiol Heart Circ Physiol 2008;294:H1388-97
  • Chen IY, Lypowy J, Pain J, et al. Histone H2A.z is essential for cardiac myocyte hypertrophy but opposed by silent information regulator 2α. J Biol Chem 2006;281:19369-77
  • Sano M, Abdellatif M, Oh H, et al. Activation and function of cyclin T–Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 2002;8:1310-7
  • Zhao X, Sternsdorf T, Bolger TA, et al. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol Cell Biol 2005;25:8456-64
  • Sundaresan NR, Samant SA, Pillai VB, et al. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol 2008;28:6384-401
  • Vakhrusheva O, Smolka C, Gajawada P, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008;102:703-10
  • Chan AY, Dolinsky VW, Soltys CL, et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 2008;283:24194-201
  • Cheng TH, Liu JC, Lin H, et al. Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 2004;369:239-44
  • Juric D, Wojciechowski P, Das DK, Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 2007;292:H2138-43
  • Liu Z, Song Y, Zhang X, et al. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 2005;32:1049-54
  • Pirola L, Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life 2008;60:323-32
  • Wu X, Zhang T, Bossuyt J, et al. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest 2006;116:675-82

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.